Опыт лечения волосато-клеточного лейкоза новым отечественным препаратом веро-кладрибином
https://doi.org/10.17650/1818-8346-2007-0-1-31-37
Аннотация
В отделении химиотерапии гемобластозов РОНЦ им. Н.Н.Блохина РАМН в период с июля 2005 г. по октябрь 2006 г. лечение препаратом веро-кладрибин получили 8 больных волосато-клеточным лейкозом (ВКЛ). У всех достигнута полная ремиссия. Длительность ремиссии на данный момент составляет от 1 до 12 мес у 7 больных. В течение курса терапии веро-кладриби-ном и последующего наблюдения (1—12 мес) серьезных токсических эффектов не выявлено. Веро-кладрибин хорошо переносится. Анемия IVстепени наблюдалась у одного больного, тромбоцитопения I степени — также у одного больного. Ни у одного больного не отмечалось фебрильной нейтропении. Инфекционных осложнений лечения зафиксировано не было.
Об авторах
Ю. Е. Рябухина
ГУРОНЦ им. Н.Н. Блохина, РАМН
Россия
Россия
Москва
А. Д. Ширин
ГУРОНЦ им. Н.Н. Блохина, РАМН
Россия
Россия
Москва
О. Л. Тимофеева
ГУРОНЦ им. Н.Н. Блохина, РАМН
Россия
Россия
Москва
Н. Н. Тупицын
ГУРОНЦ им. Н.Н. Блохина, РАМН
Россия
Россия
Москва
М. А. Френкель
ГУРОНЦ им. Н.Н. Блохина, РАМН
Россия
Россия
Москва
Н. А. Купрышина
ГУРОНЦ им. Н.Н. Блохина, РАМН
Россия
Россия
Москва
М. А. Волкова
ГУРОНЦ им. Н.Н. Блохина, РАМН
Россия
Россия
Москва
Список литературы
1. O'Brien S., Keating M.J. Cancer: Principles & Practice of Oncology. 7 th ed. Philadelphia, Lippincott Williams & Wilkins; 2005. p. 2133—43.
2. Bouroncle B.A., Wiseman B.K., Doan C.A. Leukemic reticuloendotheliosis. Blood 1958;13:609—30.
3. Schrek R., Donnelly WJ. “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes. Blood 1966;27:199—211.
4. Polliack A. Hairy cell leukemia:biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 2002;6:366—88; discussion 449—50.
5. Golomb H.M. Hairy cell leukemia: an unusual lymphoproliferative disease: a study of 24 patients. Cancer 1978;42:946—56.
6. Golomb H.M., Catovsky D., Golde D.W Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 1978;89(5 Pt 1):677—83.
7. Jansen J., Hermans J. Clinical staging system for hairy-cell leukemia. Blood 1982;60(3):571—7.
8. Bouroncle B.A. The history of hairy cell leukemia: characteristics of long-term survivors. Semin Oncol 1984;11(4 Suppl 2):479—85.
9. Katayama I., Yang I.P Reassessment of a cyto-chemical test for differential diagnosis of leukemic reticuloendotheliosis. Am J Clin Pathol 1977;68(2):268—72.
10. Yam L.T., Janskila A.J., Li C.Y, Lam WK. Cytochemistry of tartrate-resistant acid phosphatase: 15 years' experience. Leukemia 1987;1(4):285—8.
11. Falini B., Pulford K., Erber WN. et al. Use of a panel of monoclonal antibodies for the diagnosis of hairy cell leukaemia. An immunocyto-chemical study of 36 cases. Histopatology 1986;10(7):671—87.
12. Hsu S.M., Yang K., Jaffe E.S. Hairy cell leukemia: a B cell neoplasm with a unique antigenic phenotype. Am J Clin Pathol 1983;80(4):421—8.
13. Burns G.F, Cawley J.C., Wbrman C.P et al. Multiple heavy chain isotypes on the surface of the cells of hairy cell leukemia. Blood 1978;52(6):1132—47.
14. Renshaw B.R., Fanslow W.C., Armitage R.J. et al. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 1994;180(5):1889—900.
15. Saxon A., Stevens R.H., Golde TW T-lymphocyte variant of hairy-cell leukemia. Ann Intern Med 1978;88(3):323—36.
16. Feuer G., Green PL. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-I) and HTLV-II. Oncogene 2005;24:5996—6004.
17. Rosenblatt J.D., Golde D.W, Wachsman W et al. A second isolate of HTLV-II associated with atypical hairy-cell leukemia. N Engl J Med 1986;315(6):372—7.
18. Forconi F, Sahota S.S., Raspadori D. et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood 2004;104:3312—7.
19. Konig E.A., Kusser WC., Day C. et al. p53 mutations in hairy cell leukemia. Leukemia 2000;14:706—11.
20. Zuzel M., Cawley J.C. The biology of hairy cell. Best Pract Res Clin Haematol 2003;16:1—13.
21. Vallianatou K., Brito-Babapulle V., Matutes E. et al. p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant. Leuk Res 1999;23:1041—5.
22. Saven A., Piro L.D. In: Hematology. Basic Principles and Practice. N.Y., Edinburg-London-Tokyo; 1996. p. 1322—31.
23. Seshadri R.S., Brown E.J., Zipursky A. Leukemic reticuloendotheliosis. A failure of monocyte production. N Engl J Med 1976;295(4):181—4.
24. Yam L.T, Chandhry A.A., Janckila A.J. Impaired marrow granulocyte reserve and leukocyte mobilization in leukemic reticuloendothelio-sis. Ann Intern Med 1977;87(4):444—6.
25. Paoletti M., Bitter M.A., Vardiman J.W Hairy-cell leukemia. Morphologic, cytochemical and immunologic features. Clin Lab Med 1988;8:179—95.
26. Flandrin G., Sigaux E, Castaigne S. et al. [Hairy cell leukemia: study of the development of 211 cases]. Presse Med 1984;13:2795—9.
27. Alexandrakis M.G., fhssam EH., Kyriakou D.S. et al. Pleural effusions in hematologic malignancies. Chest 2004;125:1546—55.
28. Bouroncle B.A., Grever M.R., Kraut E.H. Treatment of hairy cell leukemia: the Ohio State University experience with deoxycoformycin. Leukemia 1987;1:350—4.
29. Copeland A.R., Bueso-Ramos C., Liu EJ. et al. Molecular study of hairy cell leukemia variant with biclonal paraproteinemia. Arch Pathol Lab Med 1997;121:150—4.
30. Dearden C.E., Matutes E., Hilditch B.L. et al. Long-term follow-up of patients with hairy cell leukemia after treatment with pentostatin or cladribine. Br J Haematol 1999;106:515—9.
31. Hakimian D., Tallman M.S., Hogan D.K. et al. Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia. Clin Oncol 1994;12:268—72.
32. Mercieca J., Puga M., Matutes E. et al. Incidence and significance of abdominal lym-phoadenopathy in hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl 1):79—83.
33. Rose C., Auxenfants E., Noel M.P et al. [Tuberculosis, mycobacterium infection and hairy cell leukemia]. Presse Med 1997;26:110—4.
34. Wblfe D.W, Scopelliti J.A., Boselli B.D. Leukemic meningitis in a patient with hairy cell leukemia. A case report. Cancer 1984;54:1085—7.
35. Clore L.S. Jr., Stafford C.T. Chronic urticaria as a presenting sign of hairy cell leukemia. Allergy Asthma Proc 1999;20:51—5.
36. Mainwaring C.J., Wilewska R., Snowden J. et al. Fatal cold anti-i autoimmune haemolytic anaemia complicating hairy cell leukemia. Br J Haematol 2000;109:641—3.
37. Richard C., Sedano M.C., Mazorra F. et al. Hairy-cell leukemia associated with auto-immune disorders in the form of a ‘lupus-type’ anticoagulant and a positive direct Coombs’test. Acta Haematol 1986;75:181—2.
38. Rios R., Gascon E, Sole E et al. [Analysis of response to interferon alpha-2b and the significance of antinuclear antibodies in hairy cell leukemia]. Med Clin (Barc) 1996;106:583—5.
39. Shpilberg O., Ehrenfeld M., Berkovitz M. et al. Hairy cell leukemia with an autoimmune syndrome, paraproteinemia and cryoglobulinemia. South Med J 1989;82:1552—4.
40. V&rnhes J.P, Schaeverbeke T, Each J. et al. Chronic immunity-driven poly-arthritis in hairy cell leukemia. Report of a case and review of the literature. Rev Rhum Engl Ed 1997;64:578—81.
41. Westbrook C.A., Golde D.W Autoimmune disease in hairy-cell leukemia: clinical syndromes and treatment. Br J Haematol 1985;61:349—56.
42. Bernstein L., Newton P., Ross R.K. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res 1990;50(12):3605—9.
43. Erassoldati A., Lamparelli T, Federico M. et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma 1994;13(3—4): 307—16.
44. Burke J.S., Byrne G.E., Rappaport H. Hairy cell leukemia (leukemic reticuloendotheliosis). I. A clinical pathologic study of 21 patients. Cancer 1974;33(5):1339—42.
45. Catovsky D., Pettit J.E., Galton D.A et al. Leukaemic reticuloendotheliosis ('Hairy' cell leukaemia): a distinct clinico-pathological entity. Br J Haematol 1974;26(1):9—27.
46. Elandrin G., Siqaux E, Sebahoun G., Bouffette P. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 1984;11 (4 Suppl 2):458—71.
47. Quesada J.R., Reuben J., Manning J.T et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310(1):15—8.
48. Elandrin G., Sigaux E, Castaigne S., Billard C. et al. Treatment of hairy cell leukemia with recombinant a-interferon: quantitative study of bone marrow changes during the first months of treatment. Blood 1986;67:817—20.
49. Capnist G., Eederico M., Chisesi T et al. Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL). Leuk Lymphoma 1994;14:457—64.
50. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006;32(5):365—76.
51. Carson D.A., Wasson D.B., Kaye J. et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980;77(11):6865—9.
52. Saven A., Piro L.D. Treatment of hairy cell leukemia. Blood 1992;79(5):1111—20.
53. Kearns C.M., Blakley R.L., Santana V.M., Crom W.R. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 1994;54(5):1235—9.
54. Tallman M.S., Hakiman D. Purine nukleo-side analogs: emerging roles in indolent lympho-proliferative disorders. Blood 1995;86:2463—74.
55. Kraut E.H., Bouroncle B.A., Grecer M.R. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989;7(2):168—72.
56. Piro LD., Carrera C.J., Carson D.A., Blutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;332(16):1117—21.
57. Robak T, Blasinska-Morawiec M., Krykowski E. et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996;22(1—2):107—11.
58. Else M., Ruchlemer R., Osuji N. et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2442—8.
59. Jehn U., Bartl R., Dietzfelbinder H. et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18(19):1476—81.
60. Chadha P, Rademaker AW, Mendiratta P et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term followup of the Northwestern University experience. Blood 2005;106:241—46.
61. Estey E.H., Kurzrock R., Kantarjian H.M. et al. Treatment of hairy cell leukemia with 2- chlorodeoxyadenosine (2-CdA). Blood 1992;79:882—7.
62. Tallman M.S., Hakimian D., Variakojis D. et al. A single cycle of 2- chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992;80(9):2203—9.
63. Piro L.D., Ellison D.J., Saven A. The Scripps Clinic experience with 2- chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl 1):121—5.
64. Juliusson G., Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chlorodeoxyadenosine (2-CdA): Relationship to opportunistic infections. Blood 1992;79:888—94.
65. Hoffman M.A., Janson D., Rose E., Raj KR. Treatment of hairy cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 1997;15:1138—42.
66. Carson D.A., Carrera C.J., Wasson D.B. et al. Programmed cell death and adenine deoxynu-cleotide metabolism in human lymphocytes. Adv Enzyme Regul 1988;27:395—404.
67. Carson D.A., Leoni L.M. Hairy-cell leukemia as a model for drug development. Best Pract Res Clin Haematol 2003;16:83—9.
68. Blasinska-Morawiec M., Robak T, Krykowski E. et al. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine- a report of three cases. Leuk Lymphoma 1997;25:381—85.
69. Mercieca J., Matutes E., Emmett E. et al. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol 1996;93:409—11.
70. Robak T, Blasinska-Morawiec M., Blonski J. et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999;62:49—56.
71. Tallman M.S., Zakarija A. Hairy cell leukemia: survival and relapse. Long-term followup of purine analog-based therapy and approach for relapsed disease. Transfus Apher Sci 2005;32:99—103.
72. Zinzani PL., Tani M., Marchi E. et al. Longterm follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004;89(3):309—13.
73. Tallman M.S., Hakimian D., Zanzig C. et al. Relapse of hairy cell leukemia (HCL) after 2-chlorodeoxyadenosine (2-CdA) therapy: Longterm follow-up of 99 patients (abstr). Blood 1996;88:1954—59.
74. Lauria E, Rondelli D., Zinzani PL. et al. Long-lasting complete remission in patients treated with 2-CdA: A 5-year survey. Leukemia 1997;11(5):629—32.
75. Аль-Ради Л.С., Пивник А.В., Моисеева ТН. и др. В кн.: 5-й Российский национальный конгресс «Человек и лекарство». М.; 1998. с. 471.
76. Dearden C., Catovsky D. Deoxyformycin in the treatment of mature B-cell malighancies. Leuk. Lymphoma 1990;1:179—85.
77. Legrand O., Vekhoff A., Marie J.P et al. Treatment of hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine (2-CdA): identification of parameters predictive of adverse effects. Br J Haematol 1997;99(1):165—7.
78. EurederW, Wbltermann A. et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine). Wien Klin Wochenschr 1999;23:111(24):1027—30.
Рецензия
Для цитирования:
Рябухина Ю.Е., Ширин А.Д., Тимофеева О.Л., Тупицын Н.Н., Френкель М.А., Купрышина Н.А., Волкова М.А. Опыт лечения волосато-клеточного лейкоза новым отечественным препаратом веро-кладрибином. Онкогематология. 2007;(1):31-37. https://doi.org/10.17650/1818-8346-2007-0-1-31-37
For citation:
Ryabukhina Yu.E., Shirin A.D., Timofeeva O.L., Tupitsyn N.N., Frenkel M.A., Kupryshina N.A., Volkova M.A. Experience of treatment of hairy cell leukemia with new drug Vero-cladribine. Oncohematology. 2007;(1):31-37. (In Russ.) https://doi.org/10.17650/1818-8346-2007-0-1-31-37
Просмотров:
171
Послать статью по эл. почте 